Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 1
2006 3
2007 2
2008 1
2010 2
2011 4
2012 5
2013 1
2014 2
2015 3
2016 3
2017 1
2018 6
2019 6
2020 3
2021 14
2022 9
2023 10
2024 6
2025 6
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance. Poeschel V, et al. Among authors: marks r. Lancet. 2019 Dec 21;394(10216):2271-2281. doi: 10.1016/S0140-6736(19)33008-9. Lancet. 2019. PMID: 31868632 Clinical Trial.
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome.
Vinnakota JM, Biavasco F, Schwabenland M, Chhatbar C, Adams RC, Erny D, Duquesne S, El Khawanky N, Schmidt D, Fetsch V, Zähringer A, Salié H, Athanassopoulos D, Braun LM, Javorniczky NR, Ho JNHG, Kierdorf K, Marks R, Wäsch R, Simonetta F, Andrieux G, Pfeifer D, Monaco G, Capitini C, Fry TJ, Blank T, Blazar BR, Wagner E, Theobald M, Sommer C, Stelljes M, Reicherts C, Jeibmann A, Schittenhelm J, Monoranu CM, Rosenwald A, Kortüm M, Rasche L, Einsele H, Meyer PT, Brumberg J, Völkl S, Mackensen A, Coras R, von Bergwelt-Baildon M, Albert NL, Bartos LM, Brendel M, Holzgreve A, Mack M, Boerries M, Mackall CL, Duyster J, Henneke P, Priller J, Köhler N, Strübing F, Bengsch B, Ruella M, Subklewe M, von Baumgarten L, Gill S, Prinz M, Zeiser R. Vinnakota JM, et al. Among authors: marks r. Nat Cancer. 2024 Aug;5(8):1227-1249. doi: 10.1038/s43018-024-00764-7. Epub 2024 May 13. Nat Cancer. 2024. PMID: 38741011
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G. Nowakowski GS, et al. Among authors: marks r. Ann Hematol. 2023 Jul;102(7):1773-1787. doi: 10.1007/s00277-023-05196-4. Epub 2023 May 12. Ann Hematol. 2023. PMID: 37171597 Free PMC article.
Teaming up for CAR-T cell therapy.
Wäsch R, Munder M, Marks R. Wäsch R, et al. Among authors: marks r. Haematologica. 2019 Dec;104(12):2335-2336. doi: 10.3324/haematol.2019.228676. Haematologica. 2019. PMID: 31787616 Free PMC article. No abstract available.
Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response.
Apostolova P, Kreutmair S, Toffalori C, Punta M, Unger S, Burk AC, Wehr C, Maas-Bauer K, Melchinger W, Haring E, Hoefflin R, Shoumariyeh K, Hupfer V, Lauer EM, Duquesne S, Lowinus T, Gonzalo Núñez N, Alberti C, da Costa Pereira S, Merten CH, Power L, Weiss M, Böke C, Pfeifer D, Marks R, Bertz H, Wäsch R, Ihorst G, Gentner B, Duyster J, Boerries M, Andrieux G, Finke J, Becher B, Vago L, Zeiser R. Apostolova P, et al. Among authors: marks r. Br J Haematol. 2023 Oct;203(2):264-281. doi: 10.1111/bjh.19007. Epub 2023 Aug 4. Br J Haematol. 2023. PMID: 37539479 Clinical Trial.
[Dermatological conditions requiring intensive care treatment].
Marks C, Widmeier E, Marks R, Kardaun S. Marks C, et al. Among authors: marks r. Med Klin Intensivmed Notfmed. 2025 Mar;120(2):170-182. doi: 10.1007/s00063-024-01239-4. Epub 2025 Feb 13. Med Klin Intensivmed Notfmed. 2025. PMID: 39948146 Review. German.
Signaling by small GTPases in the immune system.
Scheele JS, Marks RE, Boss GR. Scheele JS, et al. Among authors: marks re. Immunol Rev. 2007 Aug;218:92-101. doi: 10.1111/j.1600-065X.2007.00530.x. Immunol Rev. 2007. PMID: 17624946 Review.
Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance.
Schmidt C, Scheubeck G, Jurinovic V, Sökler M, Forstpointner R, Buske C, Viardot A, Keller U, Graeven U, Marks R, Hänel M, Liersch R, Dürig J, Pott C, Hoster E, Unterhalt M, Hiddemann W. Schmidt C, et al. Among authors: marks r. Haematologica. 2025 Dec 1;110(12):3022-3031. doi: 10.3324/haematol.2024.287162. Epub 2025 Jun 12. Haematologica. 2025. PMID: 40501414 Free PMC article. Clinical Trial.
79 results